1
|
Zhu C, Baumgarten N, Wu M, Wang Y, Das AP, Kaur J, Ardakani FB, Duong TT, Pham MD, Duda M, Dimmeler S, Yuan T, Schulz MH, Krishnan J. CVD-associated SNPs with regulatory potential reveal novel non-coding disease genes. Hum Genomics 2023; 17:69. [PMID: 37491351 PMCID: PMC10369730 DOI: 10.1186/s40246-023-00513-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Accepted: 07/12/2023] [Indexed: 07/27/2023] Open
Abstract
BACKGROUND Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Genome-wide association studies (GWAS) have identified many single nucleotide polymorphisms (SNPs) appearing in non-coding genomic regions in CVDs. The SNPs may alter gene expression by modifying transcription factor (TF) binding sites and lead to functional consequences in cardiovascular traits or diseases. To understand the underlying molecular mechanisms, it is crucial to identify which variations are involved and how they affect TF binding. METHODS The SNEEP (SNP exploration and analysis using epigenomics data) pipeline was used to identify regulatory SNPs, which alter the binding behavior of TFs and link GWAS SNPs to their potential target genes for six CVDs. The human-induced pluripotent stem cells derived cardiomyocytes (hiPSC-CMs), monoculture cardiac organoids (MCOs) and self-organized cardiac organoids (SCOs) were used in the study. Gene expression, cardiomyocyte size and cardiac contractility were assessed. RESULTS By using our integrative computational pipeline, we identified 1905 regulatory SNPs in CVD GWAS data. These were associated with hundreds of genes, half of them non-coding RNAs (ncRNAs), suggesting novel CVD genes. We experimentally tested 40 CVD-associated non-coding RNAs, among them RP11-98F14.11, RPL23AP92, IGBP1P1, and CTD-2383I20.1, which were upregulated in hiPSC-CMs, MCOs and SCOs under hypoxic conditions. Further experiments showed that IGBP1P1 depletion rescued expression of hypertrophic marker genes, reduced hypoxia-induced cardiomyocyte size and improved hypoxia-reduced cardiac contractility in hiPSC-CMs and MCOs. CONCLUSIONS IGBP1P1 is a novel ncRNA with key regulatory functions in modulating cardiomyocyte size and cardiac function in our disease models. Our data suggest ncRNA IGBP1P1 as a potential therapeutic target to improve cardiac function in CVDs.
Collapse
Affiliation(s)
- Chaonan Zhu
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
| | - Nina Baumgarten
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- German Center for Cardiovascular Research, Partner Site Rhein-Main, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
| | - Meiqian Wu
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
| | - Yue Wang
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
| | - Arka Provo Das
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
| | - Jaskiran Kaur
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
| | - Fatemeh Behjati Ardakani
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- German Center for Cardiovascular Research, Partner Site Rhein-Main, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
| | - Thanh Thuy Duong
- Genome Biologics, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany
| | - Minh Duc Pham
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
- Department of Medicine III, Cardiology/Angiology/ Nephrology, Goethe University Hospital, Frankfurt, Germany
- Genome Biologics, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany
| | - Maria Duda
- Genome Biologics, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany
| | - Stefanie Dimmeler
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany
- German Center for Cardiovascular Research, Partner Site Rhein-Main, 60590, Frankfurt Am Main, Germany
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany
| | - Ting Yuan
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany.
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany.
- Department of Medicine III, Cardiology/Angiology/ Nephrology, Goethe University Hospital, Frankfurt, Germany.
| | - Marcel H Schulz
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany.
- German Center for Cardiovascular Research, Partner Site Rhein-Main, 60590, Frankfurt Am Main, Germany.
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany.
| | - Jaya Krishnan
- Institute for Cardiovascular Regeneration, Goethe University, 60590, Frankfurt Am Main, Germany.
- German Center for Cardiovascular Research, Partner Site Rhein-Main, 60590, Frankfurt Am Main, Germany.
- Cardio-Pulmonary Institute, Goethe University Hospital, 60590, Frankfurt Am Main, Germany.
- Department of Medicine III, Cardiology/Angiology/ Nephrology, Goethe University Hospital, Frankfurt, Germany.
| |
Collapse
|
2
|
Song B, Dai D, Liu S, Zhu Z, Ding F, Zhu J, Zhang R. Optimal timing of coronary angiograms for patients with chronic kidney disease: association between the duration of kidney dysfunction and SYNTAX scores. Ren Fail 2021; 43:307-312. [PMID: 33538236 PMCID: PMC8901285 DOI: 10.1080/0886022x.2021.1880936] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Background Chronic kidney disease (CKD) is associated with an increased risk of the progression of coronary artery disease (CAD). However, there are few data on the relationship between CAD severity and the duration of CKD. This study assessed the predictive value of the duration of kidney dysfunction in CKD patients with CAD severity. Methods In 145 patients (63.4% male, n = 92; mean age, 68.8 ± 12.8 years) with CKD, severity of CAD was assessed by coronary angiography and quantified by SYNTAX scores, and duration of kidney dysfunction was either assessed by checking historical biochemical parameters of individuals or was based on enquiries. Results Patients with high SYNTAX scores (≥ 22) had a greater prevalence of cardiovascular risk factors including age, gender, history of heart failure and smoking. In CKD patients, SYNTAX scores were positively correlated to duration of CKD and serum uric acid (UA), and negatively correlated to high-density lipoprotein-cholesterol (HDL-C) and ApoA1 levels. Univariate binary logistic regression and multivariate logistic analyses showed that SYNTAX scores correlated significantly with CKD duration, UA, and HDL-C. Receiver-operating characteristic analysis was used to explore a time point when coronary angiography application was economical and effective and yielded a Youden index of 6.5 years. Conclusions Together, our results demonstrated that the duration of kidney dysfunction was an independent correlate of the severity of CAD in patients with CKD. Our findings suggest that coronary angiography should be considered for CKD patients with renal insufficiency having lasted for more than 6.5 years.
Collapse
Affiliation(s)
- Bei Song
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Daopeng Dai
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Shengjun Liu
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Zhengbin Zhu
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Fenghua Ding
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Jinzhou Zhu
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| | - Ruiyan Zhang
- Department of Vascular & Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
| |
Collapse
|
3
|
Daniels GH, Hegedüs L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JFE, Derving Karsbøl J, Moses AC, Buse JB, Tuttle RM. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab 2015; 17:477-86. [PMID: 25656058 PMCID: PMC4405040 DOI: 10.1111/dom.12444] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Revised: 01/18/2015] [Accepted: 01/31/2015] [Indexed: 01/31/2023]
Abstract
AIMS To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization. METHODS The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high risk of cardiovascular disease at 410 centres worldwide. People with baseline serum calcitonin ≤ 50 ng/l were randomized to liraglutide once daily or placebo and will be followed for up to 5 years. Serum calcitonin was measured at baseline and will be measured annually thereafter. An independent committee of thyroid experts will oversee calcitonin monitoring throughout the trial and will review all calcitonin concentrations ≥ 20 ng/l. RESULTS The mean age of participants was 64.3 ± 7.2 years, 64.3% were men, and mean the body mass index was 32.5 ± 6.3 kg/m(2). The median (interquartile range) baseline serum calcitonin values were 3.9 (1.0 to >7.6) ng/l in men and 1.0 (1.0 to >1) ng/l in women. Serum calcitonin was >10 ng/l in 14.6% of men and in 0.96% of women. In sex-specific multivariable linear analysis of covariance models, a reduced glomerular filtration rate (GFR) was associated with higher serum calcitonin concentrations that were statistically significant. A 20 ml/min/1.73 m(2) decrease in estimated GFR (eGFR) was associated with a 14% increase in serum calcitonin in women and an 11% increase in men. CONCLUSIONS In the LEADER population, the prevalence of elevated serum calcitonin concentrations at baseline was high, and there was an inverse association between eGFR and serum calcitonin concentrations.
Collapse
Affiliation(s)
- G H Daniels
- Thyroid Unit and Department of Medicine, Massachusetts General Hospital, Harvard Medical SchoolBoston, MA, USA
- Correspondence to: Gilbert H. Daniels, MD, Massachusetts General Hospital, Thyroid Unit ACC 730, Boston, MA 02114, USA. E-mail:
| | - L Hegedüs
- Department of Endocrinology and Metabolism, Odense University Hospital, University of Southern DenmarkOdense, Denmark
| | - S P Marso
- Division of Cardiology, Department of Internal Medicine, University of Texas SouthwesternDallas, TX, USA
| | - M A Nauck
- DiabeteszentrumBad Lauterberg, Germany
| | - B Zinman
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of TorontoToronto, Canada
| | - R M Bergenstal
- International Diabetes Center at Park NicolletMinneapolis, MN, USA
| | - J F E Mann
- Dept. of Nephrology, Hypertension & Rheumatology, Friedrich Alexander University of ErlangenMunchen, Germany
| | | | | | - J B Buse
- Department of Medicine, University of North Carolina School of MedicineChapel Hill, NC, USA
| | - R M Tuttle
- Memorial Sloan-Kettering Cancer CenterNew York, NY, USA
| |
Collapse
|
4
|
Gonçalves FLC, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moysés RMA. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 2014; 15:190. [PMID: 25465028 PMCID: PMC4265422 DOI: 10.1186/1471-2369-15-190] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 11/27/2014] [Indexed: 01/05/2023] Open
Abstract
Background Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification. However, whether high circulating Scl is also a risk factor for death is not well established. The purpose of this study was to test whether serum Scl would be associated with mortality. Methods we measured serum Scl in a hemodialysis patients’ cohort, which was followed during a ten-year period. Competing risk regression models were applied, as during the follow-up, patients were exposed to both events kidney transplant and death. Results Ninety-one patients aged 42.3 ± 18.8 years (55% of male gender, 15% of diabetes) were included. During the follow-up, 32 patients underwent kidney transplant and 26 patients died. Non-survivals presented higher FGF23, higher Scl and lower creatinine. There was an association between all-cause mortality and higher Scl (HR = 2.2), higher age (HR = 1.04) and presence of diabetes (HR = 2.27), by competing risk analyses. Even including potential markers of mortality, as creatinine, FGF 23, and gender, Scl, age and diabetes remained significantly related to higher mortality. Conclusion Serum Scl is an independent predictor of mortality in dialysis patients. However, whether clinical interventions to modulate Scl would be able to improve these patients survival needs to be determined.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Rosa M A Moysés
- Nephrology Division, Universidade de São Paulo, São Paulo, Brazil.
| |
Collapse
|
5
|
Walton TA, Nishtar S, Lumb PJ, Crook MA, Marber MS, Gill J, Wierzbicki AS. Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain. Int J Clin Pract 2014; 68:1473-7. [PMID: 25283732 DOI: 10.1111/ijcp.12520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE To determine the relationship between troponin-T levels and atheroma burden in Pakistanis presenting to an ambulatory centre with chest pain. METHODS A prospective case-control study of 400 patients selected for presence/absence of angiographic disease referred between 2001 and 2003. A comprehensive cardiovascular disease (CVD) risk factor profile was assessed including demographics, environmental and biochemical risk factors including insulin resistance and troponin-T levels. Coronary atheroma burden was quantified by Gensini score. RESULTS Clinically significant elevated troponin-T levels (> 30 pmol/l) were found in 40 patients (10%) with equal numbers in groups selected with or without angiographic disease. Troponin-T elevation (> 13 pmol/l) was present in 59 vs. 47 patients (30% vs. 24%; p = 0.04). Troponin-T levels did not correlate with any measured demographical, environmental, drug therapy or biochemical risk factor. No difference was found in concentrations of lipids, apolipoproteins, insulin resistance, C-reactive protein or sialic acid in cohorts stratified by troponin-T concentrations. In univariate analysis comparing patients with high (> 30 pmol/l) and low troponin-T levels (< 13 pmol/l) higher plasma total protein (91 g/l vs. 85 g/l; p = 0.01), increased immunoglobulin levels (41 g/l vs. 36 g/l; p = 0.02) and prevalence of hyperparathyroidism (40% vs. 21%; p = 0.04) were associated with higher troponin-T concentrations. CONCLUSIONS This study shows that measurement of troponin-T is not an alternative to imaging in an Indian asian population, but that it does identify a separate potentially high-risk population that would not be identified by the use of imaging alone which is potentially at higher risk of CVD events.
Collapse
|
6
|
Unal HU, Çelik M, Gökoğlan Y, Çetinkaya H, Gök M, Karaman M, Yilmaz Mİ, Eyileten T, Oğuz Y. Mitral annular calcification and the serum osteocalcin level in patients with chronic kidney disease. Ren Fail 2014; 36:1481-5. [PMID: 25224152 DOI: 10.3109/0886022x.2014.962421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE To determine the relationships between inflammatory mediators, mitral annular calcification (MAC), and osteocalcin in patients with chronic kidney disease (CKD). MATERIALS AND METHODS Echocardiographic data for 60 patients diagnosed as CKD were retrospectively evaluated. The patients were divided into 2 groups; patients with MAC (MAC+ group) and patients without MAC (MAC- group). The relationships between biochemical markers-including osteocalcin-and MAC were evaluated. RESULTS The study included 19 female and 41 male patients. In all, 29 patients were MAC+ and 31 were MAC-. High-sensitive C-reactive protein (hsCRP) and osteocalcin levels were significantly higher in the MAC+ group (p < 0.05). The eGFR was lower, serum calcitonin (we could not obtain calcitonin data for 15 patients), Ca, PO4, CaxPO4, the erythrocyte sedimentation rate, red cell distribution width, the neutrophil/Lymphocyte rate, and PTH were higher in the MAC+ group; however, the differences between the groups were not significant (p > 0.05). The mitral E/A ratio, mitral peak Ea velocity, tricuspid E/A ratio, hsCRP, and the osteocalcin level were strongly correlated with MAC. Multivariate logistic regression analysis showed that only the osteocalcin level and mitral E/A ratio were independent variables, each with an independent effect on MAC. CONCLUSION CKD patients in the MAC+ group had higher osteocalcin levels than those in the MAC- group, and left ventricular diastolic dysfunction was more common in the MAC+ group.
Collapse
|
7
|
Negri AL. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease. Int Urol Nephrol 2013; 46:9-17. [PMID: 23296792 DOI: 10.1007/s11255-012-0370-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Accepted: 12/17/2012] [Indexed: 12/18/2022]
Abstract
Fibroblast growth factor-23 (FGF-23) has emerged as an important hormone involved in phosphorus and vitamin D homeostasis. Chronic kidney disease (CKD) is the most common clinical condition in which FGF-23 levels are persistently and markedly elevated. Abnormal phosphate homeostasis and high circulating levels of FGF-23 are early complications of CKD. Although increases in FGF-23 levels may help maintain serum phosphate levels in the normal range in CKD, the long-term effects of its sustained elevated levels are unclear. Patients with CKD have high risks of developing end-stage renal disease (ESRD), cardiovascular disease, and premature death. Recent prospective studies in populations with predialysis CKD, ESRD on hemodialysis, and kidney transplant recipients demonstrate that elevated FGF-23 levels are independently associated with cardiovascular events and mortality. It was originally thought that FGF-23 was only a biomarker of disturbed phosphate balance; however, recent studies have shown that FGF-23 can have a direct effect on the heart, inducing left ventricular hypertrophy. This suggests that elevated FGF-23 levels may be a novel mechanism that explains the poor cardiovascular outcomes in CKD patients. Interventional studies are required in order to clarify the relation of causality between FGF-23 and cardiovascular mortality in this population.
Collapse
Affiliation(s)
- Armando Luis Negri
- Facultad de Medicina, Instituto de Investigaciones Metabólicas, Universidad del Salvador, Libertad 836 1 piso, 1012, Buenos Aires, Argentina,
| |
Collapse
|